Education
About Us
Working with TipRanks
Follow Us
QHSLab (USAQ)
OTHER OTC:USAQ
USAQ Stock Chart & Stats
$0.49
-$0.04(-14.29%)
At close: 4:00 PM EST
$0.49
-$0.04(-14.29%)
Day’s Range― - ―
52-Week Range$0.08 - $1.14
Previous CloseN/A
Volume38.37K
Average Volume (3M)6.57K
Market Cap
$8.17M
Enterprise Value$8.69M
Total Cash (Recent Filing)$158.39K
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding11,281,527
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)-4.20
Price to Sales (P/S)1.20
P/FCF Ratio17.91
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda31.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Major Debt Reduction And DeleveragingSubstantial retirement of legacy convertible debt materially lowers fixed interest burden and dilution risk, improving free cash flow and financial flexibility. This structural deleveraging supports sustained investment in product development, sales scaling, and credible governance improvements over the medium term.
New Q‑Cog Product Addressing Early Dementia DetectionQ-Cog is a durable growth driver: a cloud-native clinical tool aligned with reimbursement guidance fills a persistent clinical gap, supports recurring revenue via clinician workflows, and creates higher-margin digital revenue streams that can scale with physician adoption and value‑based care trends.
Solid Revenue Growth With Improving Gross MarginsConsistent top-line growth combined with expanding gross margins indicates improving unit economics and product-market fit. Durable margin expansion provides operating leverage potential as revenue scales, supporting long-term profitability if fixed costs remain controlled and growth continues.
Bears Say
Negative Stockholders’ EquityPersistently negative equity is a structural capital weakness that constrains financing options and exposes shareholders to dilution or solvency risk. It reduces capacity to absorb shocks, complicates lending or uplisting efforts, and makes future growth more dependent on external capital.
Ongoing Net Losses Despite Operating ImprovementContinued net losses signal that non‑operating costs or capital structure expenses are impairing bottom‑line sustainability. Without durable net profitability, the company risks re‑eroding equity or needing repeated external financing, undermining long‑term shareholder value despite operational gains.
Limited Cash Conversion And Modest Cash BufferPositive but tiny cash conversion leaves the business vulnerable to margin volatility or growth investments that temporarily increase burn. A small cash buffer and modest asset base constrain runway and elevate dependence on equity raises, which can dilute stakeholders and limit strategic optionality.
QHSLab News
USAQ FAQ
What was QHSLab’s price range in the past 12 months?
QHSLab lowest stock price was $0.08 and its highest was $1.14 in the past 12 months.
What is QHSLab’s market cap?
QHSLab’s market cap is $8.17M.
When is QHSLab’s upcoming earnings report date?
QHSLab’s upcoming earnings report date is May 18, 2026 which is in 89 days.
How were QHSLab’s earnings last quarter?
QHSLab released its earnings results on Aug 13, 2025. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is QHSLab overvalued?
According to Wall Street analysts QHSLab’s price is currently Overvalued.
Does QHSLab pay dividends?
QHSLab does not currently pay dividends.
What is QHSLab’s EPS estimate?
QHSLab’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does QHSLab have?
QHSLab has 11,281,527 shares outstanding.
What happened to QHSLab’s price movement after its last earnings report?
QHSLab reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of QHSLab?
Currently, no hedge funds are holding shares in USAQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
QHSLab
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.